{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:05:30Z","timestamp":1790373930836,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The North American opioid crisis is marked by high opioid-related mortality and morbidity, including opioid use-associated infections (OUAIs). Users of pharmaceutical and non-pharmaceutical opioids are at an increased risk of acquiring hepatitis C (HCV), human immunodeficiency virus (HIV), and other infections. No high-level evidence, however, has been synthesized regarding effectiveness of interventions to prevent OUAIs in legal, and illegal\/mixed opioid users. The aim of the study is to synthesize available systematic review (SR)\u2013level evidence on the scope and effectiveness of interventions to prevent OUAIs among opioid users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A SR of SRs approach was applied. We searched PubMed, Embase, PsycINFO, Cochrane Database of Systematic Reviews, Epistemonikos and Google Scholar from inception to September 2020. Data selection and extraction were performed independently by three researchers. Risk of bias and quality of evidence were assessed using the AMSTAR2 tool. Results were narratively synthesized. Strength of evidence for each category was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven of twelve identified SRs included interventions to prevent HCV\/HIV transmission in persons who inject drugs (PWID), including opioids. One SR evaluated interventions to prevent recurrent infectious endocarditis. There was sufficient and tentative SR of SRs-level evidence for the effectiveness of opioid substitution therapy (OST) in preventing HIV and HCV, respectively. We found tentative evidence to support effectiveness of needle\/syringe exchange programs (NSP) in HIV prevention, and sufficient evidence to support effectiveness of the combined OST and NSP in HCV prevention. There was insufficient SR-level evidence to support or discount effectiveness of other interventions to prevent OUAIs. No SR focused on non-PWID populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SR-level evidence supports the use of OST, NSP, and combined interventions for the reduction of HCV and HIV transmission in PWID. More research on prevention of other OUAIs and on prevention of OUAIs in non-PWID populations is urgently needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration:<\/jats:title><jats:p>Registered in PROSPERO on July 30, 2020. <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=195929<\/jats:ext-link>, identifier: #195929.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.749033","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T04:53:15Z","timestamp":1645505595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Effectiveness of Interventions for Prevention of Common Infections Among Opioid Users: A Systematic Review of Systematic Reviews"],"prefix":"10.3389","volume":"10","author":[{"given":"Svetlana","family":"Puzhko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Windle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"H\u00e9bert-Losier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Paraskevopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc O.","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kudrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fpubh.2017.00217","article-title":"Mobile technology to increase HIV\/HCV testing and overdose prevention\/response among people who inject drugs","volume":"5","author":"Aronson","year":"2017","journal-title":"Front Public Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"540423","DOI":"10.3389\/fpubh.2020.540423","article-title":"The opioid\/overdose crisis as a dialectics of pain, despair, and one-sided struggle","volume":"8","author":"Friedman","year":"2020","journal-title":"Front Public Health."},{"key":"B3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"Evidence synthesis-The opioid crisis in Canada: a national perspective","volume":"38","author":"Lisa","year":"2018","journal-title":"Health Promot Chronic Dis Prev Can."},{"key":"B4","unstructured":"Drug and Opioid-Involved Overdose Deaths \u2014 United States, 2017\u2013201810.15585\/mmwr.mm6911a4321916882020"},{"key":"B5","unstructured":"Opioid-related harms in Canada2020"},{"key":"B6","unstructured":"Understanding a broader range of opioid-related hospitalizations in Canada2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fpubh.2020.00210","article-title":"A structural competency curriculum for primary care providers to address the opioid use disorder, HIV, and hepatitis C syndemic","volume":"8","author":"Bagchi","year":"2020","journal-title":"Front Public Health."},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/CXA.0000000000000053","article-title":"Rates of infective endocarditis in substance use disorder and associated costs in Ontario","volume":"10","author":"Coverdale","year":"2019","journal-title":"Can J Addict."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/cid\/ciy924","article-title":"Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder","volume":"68","author":"Marks","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/j.1532-5415.2011.03586.x","article-title":"Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case\u2013control study","volume":"59","author":"Dublin","year":"2011","journal-title":"J Am Geriatr Soc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11481-011-9292-5","article-title":"Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections","volume":"6","author":"Roy","year":"2011","journal-title":"J Neuroimmune Pharmacol."},{"key":"B12","first-page":"42","article-title":"Opiates and the development of post-injury complications: a review","volume":"1","author":"Schwacha","year":"2008","journal-title":"Int J Clin Exp Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fmicb.2016.00970","article-title":"Opioids and viral infections: a double-edged sword","volume":"7","author":"Tahamtan","year":"2016","journal-title":"Front Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.7326\/M17-1907","article-title":"Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case\u2013control study","volume":"168","author":"Wiese","year":"2018","journal-title":"Ann Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/art.39462","article-title":"Opioid analgesics and the risk of serious infections among patients with rheumatoid arthritis: a self-controlled case series study","volume":"68","author":"Wiese","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B16","unstructured":"Integrated Prevention Services for HIV Infection, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis for Persons Who Use Drugs Illicitly: Summary Guidance from CDC and the U.S. Department of Health and Human Services2012"},{"key":"B17","unstructured":"The best practice recommendations for canadian harm reduction programs that provide service to people who use drugs and are at risk for HIV, HCV, and other harms: Part 2\n            StrikeC\n            WatsonTM\n            GohilH\n            MiskovicM\n            RobinsonS\n            ArkellC\n          Toronto, ON2015"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01852-w","article-title":"Effectiveness of interventions for prevention of common infections in people who use opioids: a protocol for a systematic review of systematic reviews","volume":"10","author":"Kudrina","year":"2021","journal-title":"Syst Rev."},{"key":"B19","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","year":"2013"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jclinepi.2017.10.002","article-title":"Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms","volume":"93","author":"Bougioukas","year":"2018","journal-title":"J Clin Epidemiol."},{"key":"B21","unstructured":"Overviews of reviews\n            PollockM\n            FernandesRM\n            BeckerLA\n            PieperD\n            HartlingL\n          CochraneCochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)2021"},{"key":"B22","unstructured":"BeckerL\n            OxmanA\n          Chapter 22: Overviews of reviews In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011) The Cochrane Collaboration, 20112011"},{"key":"B23","author":"Aromataris","year":"2014","journal-title":"The Joanna Briggs Institute reviewers' manual 2014: methodology for JBI umbrella reviews"},{"key":"B24","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ."},{"key":"B25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/CXA.0000000000000080","article-title":"Harm reduction for injection drug users with infective endocarditis: a systematic review","volume":"11","author":"Bahji","year":"2020","journal-title":"Can J Addict."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-017-0156-z","article-title":"Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: A systematic review with meta-analysis","volume":"14","author":"Davis","year":"2017","journal-title":"Harm Reduct J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"Cd012021","DOI":"10.1002\/14651858.CD012021.pub2","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/add.13593","article-title":"Effectiveness of pharmacy-based needle\/syringe exchange programme for people who inject drugs: A systematic review and meta-analysis","volume":"112","author":"Sawangjit","year":"2017","journal-title":"Addiction."},{"key":"B29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ije\/dyt243","article-title":"Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis","volume":"43","author":"Aspinall","year":"2014","journal-title":"Int J Epidemiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.2105\/AJPH.2014.302152","article-title":"HIV prevention for adults with criminal justice involvement: A systematic review of HIV risk-reduction interventions in incarceration and community settings","volume":"104","author":"Underhill","year":"2014","journal-title":"Am J Public Health."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1007\/s10461-013-0593-y","article-title":"Effectiveness of structural-level needle\/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review","volume":"17","author":"Abdul-Quader","year":"2013","journal-title":"AIDS Behav."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ: British Medical Journal."},{"key":"B33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.drugpo.2011.08.002","article-title":"Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review","volume":"23","author":"Sacks-Davis","year":"2012","journal-title":"Int J Drug Policy."},{"key":"B34","doi-asserted-by":"publisher","first-page":"Cd004145","DOI":"10.1002\/14651858.CD004145.pub4","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","volume":"8","author":"Gowing","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J Infect Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.drugpo.2010.02.001","article-title":"Optimal provision of needle and syringe programmes for injecting drug users: A systematic review","volume":"21","author":"Jones","year":"2010","journal-title":"Int J Drug Policy."},{"key":"B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","article-title":"Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness","volume":"25","author":"MacArthur","year":"2014","journal-title":"Int J Drug Policy."},{"key":"B38","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1360-0443.2009.02888.x","article-title":"Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews","volume":"105","author":"Palmateer","year":"2010","journal-title":"Addiction."},{"key":"B39","volume-title":"HIV prevention: a review of reviews assessing the effectiveness of interventions to reduce the risk of sexual transmission","author":"Ellis","year":"2003"},{"key":"B40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-7517-5-25","article-title":"The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned","volume":"5","author":"Abou-Saleh","year":"2008","journal-title":"Harm Reduct J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","article-title":"Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users","volume":"102","author":"Van Den Berg","year":"2007","journal-title":"Addiction."},{"key":"B42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12889-017-4210-2","article-title":"Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews","volume":"17","author":"Fernandes","year":"2017","journal-title":"BMC Public Health."},{"key":"B43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.drugpo.2017.05.027","article-title":"High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention","volume":"47","author":"Puzhko","year":"2017","journal-title":"Int J Drug Policy."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/cid\/ciy809","article-title":"Long-acting opioid use and the risk of serious infections: a retrospective cohort study","volume":"68","author":"Wiese","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1476-4431.2010.00561.x","article-title":"State-of-the-Art-Review: Immunomodulatory effects of opioids","volume":"20","author":"Odunayo","year":"2010","journal-title":"J Vet Emerg Crit Care."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.2174\/138161212803582496","article-title":"Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression","volume":"18","author":"Sacerdote","year":"2012","journal-title":"Current pharmaceutical design"},{"key":"B47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bbi.2007.12.013","article-title":"Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function","volume":"22","author":"Sacerdote","year":"2008","journal-title":"Brain Behav Immun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/sj.bjp.0701138","article-title":"Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study","volume":"121","author":"Sacerdote","year":"1997","journal-title":"Br J Pharmacol."},{"key":"B49","unstructured":"Persons Who Inject Drugs (PWID)2021"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1097\/CCM.0000000000005141","article-title":"Epidemiology. Outcomes, and trends of patients with sepsis and opioid-related hospitalizations in US hospitals","volume":"49","author":"Alrawashdeh","year":"2021","journal-title":"Crit Care Med."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.749033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T04:53:23Z","timestamp":1645505603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.749033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":50,"alternative-id":["10.3389\/fpubh.2022.749033"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.749033","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"article-number":"749033"}}